Acute Lymphoblastic Leukemia: CAR-T Cell Therapy Safety and Efficacy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Clinical Trial Progress Report
- February 1, 2021
Nagoya University announced CAR-T immunotherapy trial results in acute lymphoblastic leukemia on January 25, 2021. Initial cohort (n=3, ages 10-40) demonstrates sustained remission with excellent safety after 1+ year of treatment.
CAR-T Approach
CAR-T therapy involves genetic engineering of patient immune cells to enhance anti-tumor cytotoxicity. Nagoya and Shinshu Universities developed proprietary CAR-T technology for ALL treatment.
Patient Population
Initial Cohort: 3 patients, ages 10-40 years
Treatment Indication: Treatment-refractory or post-transplant relapsed ALL
Treatment Duration: 2 months to 1+ year
Safety Results
Treatment course demonstrates excellent safety profile with no significant toxicities reported. All patients currently remain in remission.
Next Phase
Study expanding to include pediatric cohort (ages 1-15 years) to further establish CAR-T safety profile across broader age range and validate therapeutic approach for early-onset ALL.
Clinical Significance
CAR-T immunotherapy demonstrates promising safety and efficacy in ALL, supporting further clinical development for chemotherapy-refractory and post-transplant relapsed disease.
Data Source
Nagoya University Department of Pediatrics announcement
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1